Search Results Search Sort by RelevanceMost Recent Case and Commentary Jan 2005 An Inoperable Cancer, Additional Information Faith Lagay, PhD Virtual Mentor. 2005;7(1):68-73. doi: 10.1001/virtualmentor.2005.7.1.ccas13c-0501. Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Assessment Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14a-0501. Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Comparison Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14b-0501. Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Additional Information Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14c-0501. Case and Commentary Jan 2005 Respecting Patients' End-of-Life Decisions, Option Assessment Karine Morin, LLM Virtual Mentor. 2005;7(1):87-95. doi: 10.1001/virtualmentor.2005.7.1.ccas15a-0501. Case and Commentary Jan 2005 Respecting Patients' End-of-Life Decisions Option Comparison Karine Morin, LLM Virtual Mentor. 2005;7(1):87-95. doi: 10.1001/virtualmentor.2005.7.1.ccas15b-0501. Case and Commentary Jan 2005 Respecting Patients' End-of-Life Decisions, Additional Information Karine Morin, LLM Virtual Mentor. 2005;7(1):87-95. doi: 10.1001/virtualmentor.2005.7.1.ccas15c-0501. Medicine and Society Nov 2010 Distinguishing between Restoration and Enhancement in Neuropharmacology Peter B. Reiner, MD Because regulatory approval of cognitive enhancement drugs is likely, physicians may want to consider whether they would condone the practice for restoration of function only or for enhancement purposes as well. Virtual Mentor. 2010;12(11):885-888. doi: 10.1001/virtualmentor.2010.12.11.msoc1-1011. Case and Commentary Mar 2009 Is There a Duty to Inform Patients of Phase I Trials? Commentary 1 Courtenay R. Bruce, JD and Anne Lederman Flamm, JD Physicians must ask themselves ethical questions before recommending participation in phase I trials to patients. Virtual Mentor. 2009;11(3):207-211. doi: 10.1001/virtualmentor.2009.11.3.ccas2-0903. Case and Commentary Mar 2009 Is There a Duty to Inform Patients of Phase I Trials? Commentary 2 Thomas W. LeBlanc, MD, MA and Philip M. Rosoff, MD, MA Physicians must ask themselves ethical questions before recommending participation in phase I trials to patients. Virtual Mentor. 2009;11(3):211-214. doi: 10.1001/virtualmentor.2009.11.3.ccas2-0903. Pagination First page « First Previous page ‹ Previous … Page 19 Page 20 Page 21 Page 22 Current page 23 Page 24 Page 25 Page 26 Page 27 … Next page Next › Last page Last »
Case and Commentary Jan 2005 An Inoperable Cancer, Additional Information Faith Lagay, PhD Virtual Mentor. 2005;7(1):68-73. doi: 10.1001/virtualmentor.2005.7.1.ccas13c-0501.
Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Assessment Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14a-0501.
Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Comparison Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14b-0501.
Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Additional Information Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14c-0501.
Case and Commentary Jan 2005 Respecting Patients' End-of-Life Decisions, Option Assessment Karine Morin, LLM Virtual Mentor. 2005;7(1):87-95. doi: 10.1001/virtualmentor.2005.7.1.ccas15a-0501.
Case and Commentary Jan 2005 Respecting Patients' End-of-Life Decisions Option Comparison Karine Morin, LLM Virtual Mentor. 2005;7(1):87-95. doi: 10.1001/virtualmentor.2005.7.1.ccas15b-0501.
Case and Commentary Jan 2005 Respecting Patients' End-of-Life Decisions, Additional Information Karine Morin, LLM Virtual Mentor. 2005;7(1):87-95. doi: 10.1001/virtualmentor.2005.7.1.ccas15c-0501.
Medicine and Society Nov 2010 Distinguishing between Restoration and Enhancement in Neuropharmacology Peter B. Reiner, MD Because regulatory approval of cognitive enhancement drugs is likely, physicians may want to consider whether they would condone the practice for restoration of function only or for enhancement purposes as well. Virtual Mentor. 2010;12(11):885-888. doi: 10.1001/virtualmentor.2010.12.11.msoc1-1011.
Case and Commentary Mar 2009 Is There a Duty to Inform Patients of Phase I Trials? Commentary 1 Courtenay R. Bruce, JD and Anne Lederman Flamm, JD Physicians must ask themselves ethical questions before recommending participation in phase I trials to patients. Virtual Mentor. 2009;11(3):207-211. doi: 10.1001/virtualmentor.2009.11.3.ccas2-0903.
Case and Commentary Mar 2009 Is There a Duty to Inform Patients of Phase I Trials? Commentary 2 Thomas W. LeBlanc, MD, MA and Philip M. Rosoff, MD, MA Physicians must ask themselves ethical questions before recommending participation in phase I trials to patients. Virtual Mentor. 2009;11(3):211-214. doi: 10.1001/virtualmentor.2009.11.3.ccas2-0903.